Straits Times Index
3,323.20 -6.89 (-0.21%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.74 (-0.55%) Nasdaq
17,019.88 +99.08 (+0.59%) Bitcoin USD
67,940.95 -663.45 (-0.97%) CMC Crypto 200
1,460.62 -24.08 (-1.62%)
Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 26.06 |
| Open | 25.96 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 25.96 - 25.96 |
| 52-week range | 25.04 - 32.76 |
| Volume | |
| Avg. volume | 8,793 |
| Market cap | 41.518B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 44.76 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.26 (4.84%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- Benzinga
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
On Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a restructuring after the company reported a fiscal year 2023 net profit of 144 billion yen (around $954 million), down 54.6% Y/Y. Core net profit fell 12.6% (down 15% at constant currency) to 756.8 billion yen. Takeda said it will incur restructuring costs of about 140 billion yen in fiscal year 2024 as part of a plan to optimize its workforce, cut costs, and strengthen technology. Revenue was 4.26 trillio
- GuruFocus.com
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments
- Zacks
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
